Skip to content
10-Q

Quarterly Report

Edgewise Therapeutics, Inc. EWTX

0001558370-25-006857

← back to feed
Filed
May 8, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 105.2M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $49.92M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $41.67M
Current Liabilities Q1 2025 · Mar 31, 2025 $21.12M
Current Liabilities Q1 2025 · Dec 31, 2024 $23.86M
Total Liabilities Q1 2025 · Mar 31, 2025 $24.67M
Total Liabilities Q1 2025 · Dec 31, 2024 $27.6M
Current Assets Q1 2025 · Mar 31, 2025 $443.18M
Current Assets Q1 2025 · Dec 31, 2024 $475.48M
Total Assets Q1 2025 · Mar 31, 2025 $454.39M
Total Assets Q1 2025 · Dec 31, 2024 $486.82M
Shares Diluted Q1 2025 · Mar 31, 2024 87.57M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$28.6M
Stockholders Equity Q1 2025 · Mar 31, 2024 $534.94M
Stockholders Equity Q1 2025 · Dec 31, 2023 $318.83M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.33
Eps Basic Q1 2025 · Mar 31, 2024 −$0.33
Sga Expense Q1 2025 · Mar 31, 2024 $7.06M
Rd Expense Q1 2025 · Mar 31, 2024 $27.69M
Net Income Q1 2025 · Mar 31, 2024 −$28.53M
Operating Income Q1 2025 · Mar 31, 2024 −$34.75M
Stock Issued Q1 2025 · Jan 23, 2024 21.82M sh